Back
ESC2025 Premium Access

Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry

Session: New perspectives in cardiology (1) - Lipids: drug therapy
Topic: Drug therapy
Speaker: Professor L. Rallidis (Athens, GR)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)
0 follower

6 more presentations in this session

Discussant - Lipids: drug therapy

Access
Like
Thumbnail

Suboptimal cardiovascular risk management in cancer survivors: analysis of statin prescription patterns following coronary calcium scoring

Speaker: Doctor C. Soh (Melbourne, AU)

Access
Abstract
Slides
Video
Like
Thumbnail

LDL-C targets after administration of the combination of bempedoic acid and ezetimibe in patients with acute coronary syndrome: an observational study with simulation analysis.

Speaker: Doctor G. Giunta (Buenos Aires, AR)

Access
Abstract
Slides
Video
Like
Thumbnail

Novel risk model for predicting incident atrial fibrillation in patients at high cardiovascular risk receiving omega-3 fatty acid: sub-analysis from the STRENGTH randomized clinical trial

Speaker: Doctor T. Wang (Cleveland, US)

Access
Abstract
Slides
Video
Like
Thumbnail

Pleiotropic effects of inclisiran on arterial structural and functional parameters

Speaker: Doctor M. Bellomare (Milan, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

New perspectives in cardiology (1) - Lipids: drug therapy

Speakers: Professor L. Rallidis, Doctor C. Soh, Doctor G. Giunta, Doctor T. Wang, Doctor M. Bellomare
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources